The Biomedical Advanced Research and Development Authority (BARDA) seeks to develop and procure medical countermeasures that address the consequences of chemical, biological, radiological, and nuclear (CBRN) events, as well as pandemic influenza and emerging infectious diseases. Any such threats may cause acute respiratory distress syndrome (ARDS) for which the first-line intervention is mechanical ventilation. Critically, ventilation often results in further lung damage. Patients who do not respond to mechanical ventilation are more and more frequently placed on veno-venous extracorporeal membrane oxygenation (VV-ECMO) systems, which can enable lung tissue healing by bypassing contribution of the lungs to respiratory function. VV-ECMO, however, remains labor-intensive, costly, prone to risks and complications, and ECMO capabilities are limited to a few specialized centers. The Division of Research, Innovation, and Ventures (DRIVe) in BARDA is interested in innovative approaches to sustain healthy oxygenation levels in ARDS patients as they heal naturally or await lung transplant, all the while preventing further tissue injury to already damaged lungs. Under the program Healing Lungs, DRIVe is prioritizing technologies that would make ECMO simpler to operate, safer for patients, and more widely accessible. Of particular interest are ECMO design innovations that reduce the chance of blood clot formation and hemorrhage and efforts to miniaturize the ECMO circuit into a portable unit.